These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 27627731)

  • 1. Cost-effectiveness of Intensive Blood Pressure Management.
    Richman IB; Fairley M; Jørgensen ME; Schuler A; Owens DK; Goldhaber-Fiebert JD
    JAMA Cardiol; 2016 Nov; 1(8):872-879. PubMed ID: 27627731
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Applicability and cost-effectiveness of the Systolic Blood Pressure Intervention Trial (SPRINT) in the Chinese population: A cost-effectiveness modeling study.
    Li C; Chen K; Cornelius V; Tomeny E; Wang Y; Yang X; Yuan X; Qin R; Yu D; Wu Z; Wang D; Chen T
    PLoS Med; 2021 Mar; 18(3):e1003515. PubMed ID: 33661907
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-Effectiveness of Intensive versus Standard Blood-Pressure Control.
    Bress AP; Bellows BK; King JB; Hess R; Beddhu S; Zhang Z; Berlowitz DR; Conroy MB; Fine L; Oparil S; Morisky DE; Kazis LE; Ruiz-Negrón N; Powell J; Tamariz L; Whittle J; Wright JT; Supiano MA; Cheung AK; Weintraub WS; Moran AE;
    N Engl J Med; 2017 Aug; 377(8):745-755. PubMed ID: 28834469
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of Intensive vs Standard Blood Pressure Control Among Older Patients With Hypertension.
    Liao CT; Toh HS; Sun L; Yang CT; Hu A; Wei D; Melgarejo J; Zhang ZY
    JAMA Netw Open; 2023 Feb; 6(2):e230708. PubMed ID: 36848091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative Cost-Effectiveness of Conservative or Intensive Blood Pressure Treatment Guidelines in Adults Aged 35-74 Years: The Cardiovascular Disease Policy Model.
    Moise N; Huang C; Rodgers A; Kohli-Lynch CN; Tzong KY; Coxson PG; Bibbins-Domingo K; Goldman L; Moran AE
    Hypertension; 2016 Jul; 68(1):88-96. PubMed ID: 27181996
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Cost-Effectiveness of Low-Cost Essential Antihypertensive Medicines for Hypertension Control in China: A Modelling Study.
    Gu D; He J; Coxson PG; Rasmussen PW; Huang C; Thanataveerat A; Tzong KY; Xiong J; Wang M; Zhao D; Goldman L; Moran AE
    PLoS Med; 2015 Aug; 12(8):e1001860. PubMed ID: 26241895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Telemonitoring and self-management in the control of hypertension (TASMINH2): a cost-effectiveness analysis.
    Kaambwa B; Bryan S; Jowett S; Mant J; Bray EP; Hobbs FD; Holder R; Jones MI; Little P; Williams B; McManus RJ
    Eur J Prev Cardiol; 2014 Dec; 21(12):1517-30. PubMed ID: 23990660
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of Risk of Harm Associated With Intensive Blood Pressure Management Among Patients With Hypertension Who Smoke: A Secondary Analysis of the Systolic Blood Pressure Intervention Trial.
    Scarpa J; Bruzelius E; Doupe P; Le M; Faghmous J; Baum A
    JAMA Netw Open; 2019 Mar; 2(3):e190005. PubMed ID: 30848803
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of self-management of blood pressure in hypertensive patients over 70 years with suboptimal control and established cardiovascular disease or additional cardiovascular risk diseases (TASMIN-SR).
    Penaloza-Ramos MC; Jowett S; Mant J; Schwartz C; Bray EP; Sayeed Haque M; Richard Hobbs FD; Little P; Bryan S; Williams B; McManus RJ
    Eur J Prev Cardiol; 2016 Jun; 23(9):902-12. PubMed ID: 26603745
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of the SPRINT Trial on Hypertension Management.
    Ghazi L; Oparil S
    Annu Rev Med; 2018 Jan; 69():81-95. PubMed ID: 29414255
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential Deaths Averted and Serious Adverse Events Incurred From Adoption of the SPRINT (Systolic Blood Pressure Intervention Trial) Intensive Blood Pressure Regimen in the United States: Projections From NHANES (National Health and Nutrition Examination Survey).
    Bress AP; Kramer H; Khatib R; Beddhu S; Cheung AK; Hess R; Bansal VK; Cao G; Yee J; Moran AE; Durazo-Arvizu R; Muntner P; Cooper RS
    Circulation; 2017 Apr; 135(17):1617-1628. PubMed ID: 28193605
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long Term Cost-Effectiveness of a Systolic Blood Pressure Goal of <120 mmHg in Hypertensive Patients Without Diabetes Mellitus.
    Almalki ZS; Iqbal MS; Alablan FM; Alenazi RK; Tasha AR; Daghar MF; Aldossary NM
    Value Health Reg Issues; 2020 May; 21():157-163. PubMed ID: 31978689
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost effectiveness of losartan in patients with hypertension and LVH: an economic evaluation for Sweden of the LIFE trial.
    Jönsson B; Carides GW; Burke TA; Dasbach EJ; Lindholm LH; Dahlöf B;
    J Hypertens; 2005 Jul; 23(7):1425-31. PubMed ID: 15942467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-Effectiveness of Hypertension Treatment by Pharmacists in Black Barbershops.
    Bryant KB; Moran AE; Kazi DS; Zhang Y; Penko J; Ruiz-Negrón N; Coxson P; Blyler CA; Lynch K; Cohen LP; Tajeu GS; Fontil V; Moy NB; Ebinger JE; Rader F; Bibbins-Domingo K; Bellows BK
    Circulation; 2021 Jun; 143(24):2384-2394. PubMed ID: 33855861
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intensive vs Standard Blood Pressure Control and Cardiovascular Disease Outcomes in Adults Aged ≥75 Years: A Randomized Clinical Trial.
    Williamson JD; Supiano MA; Applegate WB; Berlowitz DR; Campbell RC; Chertow GM; Fine LJ; Haley WE; Hawfield AT; Ix JH; Kitzman DW; Kostis JB; Krousel-Wood MA; Launer LJ; Oparil S; Rodriguez CJ; Roumie CL; Shorr RI; Sink KM; Wadley VG; Whelton PK; Whittle J; Woolard NF; Wright JT; Pajewski NM;
    JAMA; 2016 Jun; 315(24):2673-82. PubMed ID: 27195814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of hypertension therapy according to 2014 guidelines.
    Moran AE; Odden MC; Thanataveerat A; Tzong KY; Rasmussen PW; Guzman D; Williams L; Bibbins-Domingo K; Coxson PG; Goldman L
    N Engl J Med; 2015 Jan; 372(5):447-55. PubMed ID: 25629742
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An economic assessment of losartan-based versus atenolol-based therapy in patients with hypertension and left-ventricular hypertrophy: results from the Losartan Intervention For Endpoint reduction (LIFE) study adapted to The Netherlands.
    Boersma C; Carides GW; Atthobari J; Voors AA; Postma MJ
    Clin Ther; 2007 May; 29(5):963-971. PubMed ID: 17697915
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-Effectiveness of Screening for Primary Aldosteronism and Subtype Diagnosis in the Resistant Hypertensive Patients.
    Lubitz CC; Economopoulos KP; Sy S; Johanson C; Kunzel HE; Reincke M; Gazelle GS; Weinstein MC; Gaziano TA
    Circ Cardiovasc Qual Outcomes; 2015 Nov; 8(6):621-30. PubMed ID: 26555126
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The SPRINT Research. A Randomized Trial of Intensive versus Standard Blood-Pressure Control].
    Widimský J
    Vnitr Lek; 2016 Jan; 62(1):44-7. PubMed ID: 26967236
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes.
    CDC Diabetes Cost-effectiveness Group
    JAMA; 2002 May; 287(19):2542-51. PubMed ID: 12020335
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.